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Thermostabilitya b s t r a c t
Rift Valley Fever (RVF) is an emerging zoonotic disease present in sub-Saharan Africa and the Arabian
Peninsula. Vaccination of cattle against RVF with a RVF virus clone 13 (CL13) strain has proven to be efﬁ-
cacious, and avoids the side effects caused by other available live vaccines. In order to determine the tem-
perature stability of the CL13 vaccine, lyophilized and liquid forms were tested and titrated for the
presence of live virus after storage for various time periods at various temperatures. Results showed that
the virus could be stored lyophilized at 4 C for more than 12 months, with no reduction of infectivity.
However, the vaccine was shown to be unstable at room temperature and at 37 C in both lyophilized
and liquid forms. This data shows that the CL13 vaccine is highly reliant on a cold chain, emphasizing
the need for the vaccine to be made thermostable in order to allow for efﬁcient vaccine storage and deliv-
ery in endemic tropical countries.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Rift Valley Fever Virus (RVFV) belongs to the family of Bunyavir-
idae, genus Phlebobirus [1]. It was ﬁrst identiﬁed in 1931 in Kenya
after isolation from a sheep in the Rift Valley [2]. More than 40 spe-
cies of mosquitoes (primarily the genus Aedes, Culex, Anopheles) are
likely to transmit the virus [3].
RVF infection is usually unapparent in humans, but can be asso-
ciated with a moderate to severe non-fatal inﬂuenza-like illness
[4,5]. In some cases the virus can however be lethal for humans
and it results in major losses in the livestock industry. RVFV causes
disease in camels [6], sheep, cattle and goats [2]. The disease in
these species is characterized by high rates of abortion, high levels
of mortality in neonates and hepatic necrosis. Mortality in adult
cattle and sheep is 10% and 20% respectively [7]. However, the
mortality in neonatal sheep and spontaneous abortion rates in
pregnant ewes are close to 100% [8].The ﬁrst vaccine for RVF was developed in South Africa by
attenuation of a ﬁeld isolate (Smithburn) by serial passages in
mouse brains [9]. This live vaccine has the advantage of inducing
early and long-term immunity after a single injection [10]. Its
use is however not recommended in the early stages of pregnancy
in ewes due to residual virulence [11,12], as it is reported to induce
a low percentage of abortions and stillbirth [13]. There is also a
commercial inactivated vaccine available which is favored for use
in non-endemic areas and during disease outbreak situations;
however this vaccine is expensive and requires an initial course
of two vaccines and then annual revaccination for optimal protec-
tion [14,15].
RVFV Clone 13 (CL13) is a natural live attenuated RVFV mutant,
which was isolated from a non fatal human case of RVF [16]. The
CL13 has a large deletion in the non-structural protein coded by
the S segment (NSs), which has been identiﬁed as a virulence factor
[12]. An evaluation of efﬁcacy and safety of the CL13 vaccine in
ewes at different stages of pregnancy indicated that the vaccine
did not induce clinical manifestation of RVF such as abortion in
pregnant ewes, teratogeny in their offspring, or pyrexia in vacci-
nated animals. Vaccination with CL13 vaccine also prevented clin-
ical RVF following virulent challenge [17,18].
The objectives of this study were therefore to measure the
stability of the CL13 vaccine strain, in both a lyophilized and liquid
form, at various temperatures. Knowing this information is
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in endemic tropical countries.
Material and methods
Virus growth and titration
The CL13 was passaged on baby hamster kidney cells (BHK)
grown in DMEM (Dulbecco’s modiﬁed Eagle’s) medium with 10%
calf serum. The virus was inoculated with a multiplicity of infec-
tion (MOI) of 0.01 in 25 cm2 ﬂasks containing conﬂuent layer cells
and incubated at 37 C, after a 45 min of adsorption, the medium
was added and ﬂasks incubated 6 days at 37 C. Every 24 h, a sam-
ple of supernatant (representing extracellular virus) was removed
from the ﬂasks and titrated for virus infectivity. Every 24 h one
ﬂask was frozen at 80 C and titrated for virus after thawing (rep-
resenting intracellular and extracellular virus).
Titration for virus was performed on BHK cells by making ten-
fold dilutions of the virus in medium. Each dilution (100 ll) was
transferred to 6 wells of a micro-titer plate, and 150 ll of cell sus-
pension was added to each well. Plates were incubated for 4 days
at 37 C in 5% CO2. The highest dilution causing cytopathic effect
in inoculated cells in 50% of the wells was calculated and expressed
as TCID 50/ml following the method described by Reed and
Muench temperature stability studies:
The virus was grown to a known titer. One aliquot was lyophi-
lized and a second aliquot was stored in the ‘wet’ form.
Aliquots of the ‘wet’ virus were stored and titrated as follows:
1. At 80 C, with aliquots of virus titrated at monthly
intervals for 18 months.
2. At +4 C, with aliquots of virus titrated every week for
9 weeks.
3. At room temperature (22–25 C), with aliquots of virus
titrated every 2 days for 10 days.
4. At 37 C, with aliquots of virus titrated every 12 h for
96 h.
5. At 45 C, with aliquots of virus titrated every 30 min for
3 h.
6. At 56 C, with aliquots of virus titrated every 10 min for
2 h.
Aliquots of the lyophilized virus were stored and titrated as
follows:
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Fig. 1. Kinetics of viral multiplication (RVFV CL13) in BHK cells.2. At room temperature (22–25 C), with aliquots of virus
titrated every day for 7 days.
3. At 37 C, with aliquots of virus titrated every day for
7 days.
Results and discussion
Kinetics of CL13 growth
The maximum titer of virus (107.6/ml) was obtained at 3 dpi
(Fig. 1). The titer of virus then decreased progressively up to 6
dpi, when it had a titer of 106.5/ml. A difference was observed be-
tween the titer of the extracellular and the total virus during the
ﬁrst and second day of infection, with the total viral titer being
higher than the titer of the extracellular virus (Fig. 1).
Temperature stability studies
The temperature stability studies carried out on both lyophi-
lized and ‘wet’ forms of the CL13 virus revealed that:
– At 80 C, the virus remained stable for at least 18 months. The
titer dropped by 0.4 log (from 106.5–106.1) in the ﬁrst 6 months
and then stabilized at 106,1 /ml for more than 12 months.
– At +4 C, the liquid form of the virus lost all its infectivity within
2 months, however the lyophilized form remained stable, with
no signiﬁcant reduction in viral titer being observed, for more
than 12 months (Fig. 2).
– At room temperature (22–25 C), the liquid form of the virus
lost all its infectivity by day 11 of storage and the titer of the
lyophilized form of the virus dropped by 1.2 logs (from 105.5
to 104.3) within 7 days of storage (Fig. 3). At 37 C, the liquid
and lyophilized form of the virus lost all infectivity by 2 and 7
dpi respectively (Fig. 3).
– The CL13 lost all its infectivity in 80 min at 56 C and the titer of
virus dropped by 1 log in 3 h at 45 C (Fig. 4).
Infection of mammalian cells with RVFV generally leads to the
production of virus followed by cell death. Billecocq and all re-
ported that, when conﬂuent cell cultures were infected with
CL13, the peak of virus production occurred after 2 or 3 dpi,
depending on the multiplicity of infection (MOI). Viral replication
was associated with cells rounding up, detaching from the plate
and dying after 5–6 days [16]. The same result was shown in our
study, conﬁrming that the maximum titer of the virus was ob-
tained at 3 dpi in BHK cells and complete lyses of the infected cells
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Fig. 3. Temperature stability of RVFV CL13 in a liquid and lyophilized form at room
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Fig. 4. Temperature stability of the RVFV CL13 in a liquid form at 45 C and 56 C.
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vaccines relate to the potential drop of virus titer during lyophili-
zation, improper storage conditions and/or an inability to maintain
the cold chain during the process of vaccine delivery. RVF is an
important zoonotic emerging disease and currently very few good
quality vaccines have been developed to control and prevent its
spread. CL13 is probably the safest and efﬁcacious RVFV candidate
vaccine strain currently available [12], however nothing is known
about the temperature stability of this vaccine virus in both lyoph-
ilized and liquid forms. This is the ﬁrst published study that ana-
lyzes the temperature stability of the CL13 vaccine when stored
for various time periods at various temperatures in a liquid or
lyophilized form.
Standard recommendations for the storage of similar live vac-
cines would be to store the liquid form at 80 C and the lyophi-
lized form at +4 C. This study revealed that the CL13 virus
maintained its initial viability when stored at 80 C for at least
18 months. Another study also found that 70 C was the temper-
ature of choice for storage of the RVFV van Wyk strain [17].
This study also showed that there was no loss of infectivity of
the lyophilized CL13 when stored at +4 C for up to 12 months.
The lyophilized Smithburn RVFV vaccine has an expiry date of
2 years when stored at 20 C [19]. Another RVFV live-attenuated
vaccine candidate (MP-12 strain) was developed in the 1980s bythe US Army Medical Research Institute of infectious Diseases
(USAMRIID) [20]. This vaccine however proved to be highly terato-
genic, causing fetal pathology between day 35 and 52 of preg-
nancy, in ewes vaccinated at different stages of pregnancy [21].
However, the new recombinant RVFV MP-12 with NSm deletion
was shown to be safe in pregnant sheep causing neither abortion
nor fetal malformation [22]. It has also been shown that the lyoph-
ilized MP-12 strain is stable when maintained cold, and retains full
potency following storage at 30 C [23].
At room temperature (22–25 C), in the liquid form, no live
CL13 virus was detected after 10 days storage and when the liquid
form of the virus was stored at 37 C, its infectivity disappears
completely by the fourth day of storage. Storage of the lyophilized
form of the virus at 37 C resulted in a complete loss of infectivity
by 7 days of storage. The stability of the RVFV Smithburn strain
was tested at 37.5 C and after 5 days of storage at this tempera-
ture no viral infectivity remained. At 24 h there was a 10-fold de-
crease in the titer; by 48 h there was a 10,000-fold decrease in
the titer and after 5 days there was no demonstrable infectious
virus [24].
Complete inactivation of CL13 was achieved in 80 min at 56 C
and the titer of virus dropped one log after 3 h at 45 C. When Vero
cells were infected with RVF viruses, the virus was completely
inactivated after heating for 1 h at 60 C [25].Conclusion
This study set out to measure the temperature stability of the
CL13 vaccine strain when stored for various time periods at various
temperatures in a liquid or lyophilized form. The CL13 maintained
its viability for more than 18 months when stored at -80 C in li-
quid form and for at least 12 months when stored at +4 C in the
lyophilized form. However, the CL13 virus was shown to be unsta-
ble at room temperature (22–25 C), and at 37 C, in both lyophi-
lized and liquid forms. Complete inactivation of the virus was
reached after only 80 min at 56 C.
This data raises issues about the risks associated with using the
CL13 vaccine in tropical (hot) countries without strict maintenance
of the cold chain during vaccine storage and delivery. It is clear that
the CL13 strain is a promising and effective vaccine when used to
control for RVF, and that the vaccine has reduced side effects when
compared to other available RVF live vaccines, such as the Smith-
burn vaccine. However, efforts to improve the thermostability of
this vaccine strain are needed in order to optimize its efﬁcacy
when used in the tropical climates in which RVFV is currently
circulating.References
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